Influenza A Virus, H7N9 Subtype
4
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Inactivated Subvirion H7n9 Vaccine
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals
Research Network
Common Treatments
- Inactivated Subvirion H7n9 Vaccine2
- H7n9 Anhui 2013aa Ca1
- As03 Adjuvant1
- H7n9 Plaiv1
- H7n9 Piiv1
Active Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)4
- University of Rochester1
Top Investigators
Johns Hopkins Bloomberg School of Public Health
University of Rochester
University of Rochester
University of Rochester